Shenzhen Salubris Pharmaceuticals Co., Ltd. (SHE:002294)

Market Cap	33.69B -42.6%
Revenue (ttm)	4.70B +14.6%
Net Income	673.52M +8.2%
EPS	0.60 +7.1%
Shares Out	1.11B
PE Ratio	50.69
Forward PE	n/a
Dividend	0.55 (1.81%)
Ex-Dividend Date	May 26, 2026

Volume	8,614,427
Open	30.80
Previous Close	30.19
Day's Range	30.12 - 30.80
52-Week Range	29.25 - 70.99
Beta	-0.25
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 25, 2026

About SHE:002294

Shenzhen Salubris Pharmaceuticals Co., Ltd. engages in the research, development, production, and sale of pharmaceuticals and medical devices in China. The company is involved in the production and supply of pharmaceutical products in the fields of chronic diseases, including cardiovascular and cerebrovascular diseases, diabetes, oncology, osteoporosis, anti-infective diseases, and chronic kidney diseases. It also engages in the research and development, production, and sale of high-end interventional medical devices, such as cardiovascular and...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1998
• Employees: 4,087
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 002294

Financial Performance

In 2025, SHE:002294's revenue was 4.35 billion, an increase of 8.48% compared to the previous year's 4.01 billion. Earnings were 651.50 million, an increase of 8.30%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 18, 2026

Data Sources Report a data error